Janice L. Gabrilove

Janice L. Gabrilove

Corporate Officer/Principal chez Icahn School of Medicine at Mount Sinai

Finance
Consumer Services

Profil

Dr. Gabrilove, board certified in Internal Medicine and Medical Oncology, is the Vice Chairman of Clinical Research at the Department of Medicine at the Mount Sinai Medical Center, New York, NY.
She is a professor of Medical Oncology at Mount Sinai, Director of the Hematology/Oncology Fellowship Program, and Chairperson of the Clinical Care Committee.
She is the Inventor of the American, Canadian, and European patent use of the recombinant human granulocyte colony stimulating factor in the treatment of mucositis, the coinventor of the American and Canadian patent human pluripotent granulocyte colony stimulating factor and the coinventor of the American, Canadian, and European application stimulation of bone marrow stromal and progenitor cells by human basic fibroblast growth factor.
Dr. Gabrilove has served in an advisory capacity to a number of biotech companies and served for five years on the first FDA advisory board for the approval of biologics.
She is on the Executive committee of the American Society of Hematology, and received her medical degree from the Mount Sinai School of Medicine.

Postes actifs de Janice L. Gabrilove

SociétésPosteDébut
Icahn School of Medicine at Mount Sinai Corporate Officer/Principal -
Tous les postes actifs de Janice L. Gabrilove

Anciens postes connus de Janice L. Gabrilove

SociétésPosteFin
Corporate Officer/Principal -
Voir l'expérience en détail de Janice L. Gabrilove

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Janice L. Gabrilove

Relations

47

Relations au 1er degré

2

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées1

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Janice L. Gabrilove
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT